发明申请
WO2019018445A1 POLYTHERAPY MODULATING CATHELICIDIN GENE EXPRESSION MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER CONDITIONS
审中-公开
基本信息:
- 专利标题： POLYTHERAPY MODULATING CATHELICIDIN GENE EXPRESSION MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER CONDITIONS
- 申请号：PCT/US2018/042563 申请日：2018-07-17
- 公开(公告)号：WO2019018445A1 公开(公告)日：2019-01-24
- 发明人： BARRON, Annelise E. , EVANS, Andrew K. , LIN, Jennifer S. , MCCLURE, Joshua , SHAMLOO, Mehrdad
- 申请人： MAXWELL BIOSCIENCES, INC.
- 申请人地址： 800 W Cesar Chavez Street Austin, Texas 78701 US
- 专利权人： MAXWELL BIOSCIENCES, INC.
- 当前专利权人： MAXWELL BIOSCIENCES, INC.
- 当前专利权人地址： 800 W Cesar Chavez Street Austin, Texas 78701 US
- 代理机构： FORTKORT, John A.
- 优先权： US62/533,589 20170717
- 主分类号： A61K31/12
- IPC分类号： A61K31/12 ; A61K31/593 ; A61K38/17 ; C07K14/47
摘要：
A polytherapy of orally available compounds is disclosed that synergistically modulates and induces the expression of the cathelicidin gene (CAMP), which encodes the host defense peptide LL-37. By providing a number of different CAMP-inducing compounds together at the same time, stronger gene induction is achieved than with just one or two compounds. Induction also may vary in different parts of the body, depending on which compounds are used and at what levels.The polytherapy may induce cathelicidin expression in the brain, which may help to treat or prevent Alzheimers Disease. Systemic cathelicidin gene induction may help treat numerous other conditions including Type 2 Diabetes / Metabolic Syndrome, or chronic bacterial, viral, or fungal infections associated with increased cancer risk or neurodegeneration. By increasing cellular autophagy and macroautophagy and supporting mitochondrial biogenesis and homeostasis, CAMP gene upregulation may reduce the effects of cellular aging and increase longevity.
IPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K31/00 | 含有机有效成分的医药配制品 |
| --------A61K31/12 | .酮类 |